LCK JNK 1 LLC reports 6.33% stake in Scinai ADS

LCK JNK 1 LLC reports beneficial ownership of 317,366 American Depository Shares (ADS), representing 6.33% of the class of ADS of Scinai Immunotherapeutics Ltd. The filing shows the ADS class is structured as one ADS = 4,000 ordinary shares.

Rhea-AI Filing Summary

LCK JNK 1 LLC reports beneficial ownership of 317,366 American Depository Shares (ADS), representing 6.33% of the class of ADS of Scinai Immunotherapeutics Ltd.

The filing shows the ADS class is structured as one ADS = 4,000 ordinary shares. The filing lists sole voting and dispositive power over 317,366 ADS. The document is signed by Richard J. Kertzman as Sole Member on 06/18/2026 and references 04/27/2026 in the cover area.

Insights

Corporate Governance Analyst

Entity reports a substantial passive stake of 6.33% in SCNI ADS.

The filing amends prior Schedule 13 information to show 317,366 ADS beneficially owned, with sole voting and dispositive power attributed to LCK JNK 1 LLC. The ADS ratio is disclosed as 1 ADS = 4,000 ordinary shares, which clarifies the instrument type held.

Ownership at 6.33% can be a notable disclosure threshold for shareholder reporting; subsequent filings or changes in holdings would appear in future amendments.

Key Figures

Beneficial ownership: 317,366 ADS Percent of class: 6.33% ADS conversion ratio: 1 ADS = 4,000 ordinary shares +3 more

6 metrics

Beneficial ownership 317,366 ADS reported in Schedule 13G/A

Percent of class 6.33% percent of ADS class

ADS conversion ratio 1 ADS = 4,000 ordinary shares security description

Sole voting power 317,366 shares number with sole voting power

Sole dispositive power 317,366 shares number with sole dispositive power

CUSIP 09073Q203 security identifier

Key Terms

American Depository Shares (ADS), beneficially owned, Schedule 13G/A

3 terms

American Depository Shares (ADS) financial

"American Depository Shares, each representing 4,000 Ordinary Shares"

American Depository Shares (ADS) are U.S.-listed securities issued by a bank that represent ownership of a specified number of shares in a foreign company, letting investors buy and sell that company in U.S. dollars on U.S. exchanges. They matter because they make it easier to invest in foreign firms—like buying a locally labeled product instead of importing it—affecting liquidity, dividend payments, regulatory disclosure and exposure to currency swings.

beneficially owned regulatory

"Amount beneficially owned: 317,366"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Schedule 13G/A regulatory

"SCHEDULE 13G/A (Amendment No. 2)"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does LCK JNK 1 LLC report in SCNI?

LCK JNK 1 LLC reports beneficial ownership of 317,366 ADS, equal to 6.33% of the ADS class, per the filing's figures and percentages.

What security class is reported in the Schedule 13G/A for SCNI?

The filing reports ownership of American Depository Shares (ADS), each representing 4,000 ordinary shares of Scinai Immunotherapeutics Ltd., as stated in the document.

Who has voting and dispositive power over the reported shares?

The filing states LCK JNK 1 LLC has sole voting power and sole dispositive power over 317,366 ADS, with shared powers listed as 0.

When was the Schedule 13G/A signed and who signed it?

The form is signed by Richard J. Kertzman, Sole Member on 06/18/2026, which appears as the signature date on the amendment.

What CUSIP applies to the reported ADS?

The filing lists the CUSIP for the ADS class as 09073Q203 in the cover and security description section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2026 - 09:58 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Scinai Immunotherapeutics Ltd.

(Name of Issuer)

American Depository Shares, each representing 4,000 Ordinary Shares, no par value

(Title of Class of Securities)

09073Q203

(CUSIP Number)

04/27/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 09073Q203

1

Names of Reporting Persons

LCK JNK 1 LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 317,366.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 317,366.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

317,366.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.33 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Scinai Immunotherapeutics Ltd.
(b)	Address of issuer's principal executive offices: JERUSALEM BIOPARK, 2ND FLOOR, HADASSAH EIN KEREM CAMPUS, JERUSALEM, ISRAEL 00000
Item 2.
(a)	Name of person filing: LCK JNK 1 LLC
(b)	Address or principal business office or, if none, residence: 3105 NW 107TH AVENUE SUITE 103 DORAL, Florida 33172
(c)	Citizenship: LCK JNK 1 LLC - UNITED STATES
(d)	Title of class of securities: American Depository Shares, each representing 4,000 Ordinary Shares, no par value
(e)	CUSIP No.: 09073Q203
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 317,366
(b)	Percent of class: 6.33 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: LCK JNK 1 LLC - 317,366
	(ii) Shared power to vote or to direct the vote: LCK JNK 1 LLC - 0
	(iii) Sole power to dispose or to direct the disposition of: LCK JNK 1 LLC - 317,366
	(iv) Shared power to dispose or to direct the disposition of: LCK JNK 1 LLC - 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

LCK JNK 1 LLC

Signature:	/s/ Richard J. Kertzman
Name/Title:	Richard J. Kertzman, Sole Member
Date:	06/18/2026